“Consumption” was the name people used for centuries to describe tuberculosis, the infectious disease caused by the bacterium Mycobacterium tuberculosis. The term came from how the illness appeared to literally consume its victims from within, leaving them pale, emaciated, and coughing blood as the infection slowly destroyed their lungs. It was among the leading causes of death in Europe and North America well into the 1800s, and it remains one of the deadliest infectious diseases on the planet today. The story of consumption is far older, stranger, and more current than most people realize.
Why People Called It Consumption
Before anyone understood bacteria or germ theory, the only way to name a disease was by what it looked like. Tuberculosis was a slow death. Patients lost weight steadily over weeks and months, their appetite faded, and they developed a persistent cough that often produced bloody sputum. They seemed to waste away, as though something inside was eating them alive. The word “consumption” captured that observation perfectly.
We now understand the biological machinery behind that wasting. The disease process alters appetite-regulating hormones, raising levels of some while lowering others, which suppresses hunger and disrupts normal metabolism. Patients take in fewer calories while their bodies burn more energy fighting the infection. The result is severe muscle and fat loss, a condition called cachexia, which was the visible hallmark of “dying of consumption.”1PubMed Central. Cachexia in tuberculosis in South-East Asian and African regions: knowledge gaps and untapped opportunities After effective treatment begins, those hormones normalize, appetite returns, and patients start to regain weight. That reversal is one of the clearest signs that the drugs are working.
Consumption also went by other names in different eras and regions. “The White Plague” referred to the extreme pallor of its victims. “Scrofula,” or “the King’s Evil,” described TB that settled in the lymph nodes of the neck rather than the lungs, causing grotesque swelling. In the Romantic era of the early 1800s, consumption became paradoxically fashionable in literary circles. Writers and poets like John Keats and the Brontë sisters either suffered from it or romanticized its ethereal effects. The pale, thin appearance it produced was briefly considered attractive. That glamour, of course, bore no resemblance to the reality of drowning in your own blood.
How Tuberculosis Spreads
TB is an airborne disease. When someone with active pulmonary tuberculosis coughs, sneezes, or even speaks, they release tiny droplet nuclei containing the bacteria into the air. These particles are small enough to remain suspended and be inhaled deep into the lungs of anyone nearby.2PubMed Central. Transmission and Institutional Infection Control of Tuberculosis Unlike many respiratory pathogens that require close, prolonged contact, TB can linger in indoor air for hours. Crowded, poorly ventilated spaces are where transmission happens most easily: prisons, shelters, dormitories, and overcrowded housing.
Not everyone who breathes in the bacterium gets sick. In fact, most people’s immune systems manage to contain the infection without ever developing symptoms, a state called latent TB infection. Someone with latent TB cannot spread the disease and may never know they were infected. But the bacteria are not dead. They sit dormant, walled off inside the body, potentially for decades.3PubMed Central. Latent tuberculosis infection: An overview Roughly a quarter of the world’s population is estimated to carry latent TB. Only about five to ten percent of those people will ever develop active disease in their lifetime, usually when something weakens their immune system.
What the Bacteria Do Inside the Body
Mycobacterium tuberculosis is an unusually tough organism. Its cell wall is layered with waxy lipids called mycolic acids, which are found only in mycobacteria and are essential for the bacterium’s survival and ability to cause disease.4PubMed Central. Mycolic acids: deciphering and targeting the Achilles’ heel of the tubercle bacillus That fatty armor makes the bacterium remarkably resistant to many of the immune system’s normal killing mechanisms, and it is a major reason why TB is so hard to treat. Several front-line TB drugs work specifically by disrupting the production or structure of these mycolic acids.
When TB bacteria reach the lungs, the immune system responds by forming structures called granulomas, clusters of immune cells that wall off the invaders. A granuloma can contain the bacteria and prevent disease, but it also creates a protected niche where the bacteria survive.5PubMed Central. The granuloma in tuberculosis: dynamics of a host-pathogen collusion This is the biological standoff behind latent TB. The immune system cannot eliminate the bacteria entirely, and the bacteria cannot break free. When that balance tips, because of aging, malnutrition, HIV infection, or other immune-suppressing conditions, the granulomas break down, bacteria multiply, and active disease develops. Lung tissue is progressively destroyed, creating cavities that produce the bloody cough that defined consumption.
An Ancient Companion of Humanity
TB is not a disease of civilization. Research on ancient DNA and skeletal remains has traced the relationship between humans and this pathogen back at least 70,000 years, to early human populations in Africa. It then spread across the globe alongside Homo sapiens as people migrated out of Africa, adapting to different human populations over millennia.6PubMed Central. The paleopathological evidence on the origins of human tuberculosis: a review TB has been found in ancient Egyptian mummies dating to well before 3000 BC, in pre-Columbian remains from the Americas, and in Neolithic European skeletons.7PubMed. Paleomicrobiology of Human Tuberculosis
For a long time, scientists assumed that human TB evolved from a cattle strain, Mycobacterium bovis, after humans domesticated livestock. Genetic evidence has largely overturned that idea. Analysis of ancient mycobacterial DNA from Egyptian specimens shows ancestral M. tuberculosis strains predating the animal strains, supporting the view that the human pathogen evolved from a common ancestor rather than jumping from cows to people.8PubMed Central. Paleopathology of human tuberculosis and the potential role of climate The explosive growth of TB during the Neolithic period was likely driven by larger, denser human settlements that made airborne transmission far more efficient.
How Koch Solved the Mystery
For most of history, consumption was blamed on bad air, hereditary weakness, or emotional temperament. The breakthrough came on March 24, 1882, when the German physician Robert Koch announced that he had isolated the bacterium responsible. He developed a new staining method that made the organism visible under a microscope, grew it on a special solid culture medium, and then reproduced the disease in guinea pigs, proving the chain from microbe to illness.9PubMed. Steps towards the discovery of Mycobacterium tuberculosis by Robert Koch, 1882 Koch’s work built on earlier evidence from the French physician Jean-Antoine Villemin, who had demonstrated in the 1860s that TB was transmissible, but Koch was the first to pin down exactly what caused it.
Koch later developed tuberculin, an extract from TB bacteria, hoping it would serve as a cure. It did not. But tuberculin turned out to be valuable as a diagnostic tool, the basis for the tuberculin skin test still used today.10PubMed Central. Robert Koch: centenary of the discovery of the tubercle bacillus, 1882 Koch received the Nobel Prize in 1905, and March 24 is still observed as World Tuberculosis Day.
From Sanatoria to Antibiotics
Knowing the cause of TB did not immediately provide a cure. For decades after Koch’s discovery, the main treatment was the sanatorium. Starting in the mid-1800s, facilities across Europe offered patients rest, fresh air, exercise, and balanced meals. The first sanatorium opened in Germany in 1854, and by the early twentieth century, they had spread across Europe and North America.11PubMed Central. The history of tuberculosis: the social role of sanatoria for the treatment of tuberculosis in Italy between the end of the 19th century and the middle of the 20th Sanatoria helped some patients recover and served to isolate the sick from healthy populations, but they were not a reliable cure. Many patients died there anyway.
The real turning point came in 1943 with the discovery of streptomycin by Selman Waksman and his research team. Streptomycin was the first antibiotic effective against M. tuberculosis, and it transformed a near-certain death sentence into a treatable condition. The development of a technique for producing streptomycin at large scale enabled rapid animal testing and human clinical trials.12PubMed Central. Selman A. Waksman, winner of the 1952 Nobel Prize for physiology or medicine More antibiotics followed over the next few decades, and by the mid-twentieth century, the sanatorium era was effectively over.
Modern standard treatment for drug-susceptible TB involves a combination of four antibiotics: rifampicin, isoniazid, pyrazinamide, and ethambutol, taken together during an initial intensive phase that lasts about two months, followed by a continuation phase with fewer drugs for several more months.13PubMed. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial Multiple drugs are used simultaneously because M. tuberculosis has a natural ability to develop resistance, and hitting it from several angles at once makes it far harder for resistant strains to survive. Full treatment typically takes six to nine months, which is itself a major challenge: patients who feel better after a few weeks sometimes stop taking their pills, which breeds resistance.
The TB and HIV Collision
The arrival of HIV in the 1980s breathed new life into the TB epidemic. In a person with a healthy immune system, latent TB usually stays latent. HIV systematically destroys the very immune cells, CD4+ T cells, that the body relies on to keep TB bacteria contained. In areas where both infections are common, HIV is the single most important risk factor for developing active TB.14PubMed Central. Tuberculosis and HIV Coinfection
The relationship runs both directions. TB infection accelerates HIV’s progression toward AIDS by activating the immune system in ways that help the virus replicate faster.15PubMed. Immunopathogenesis of TB-HIV Co-Infection: Mechanisms of Dual Immune Suppression and Viral-Bacterial Synergy The interaction is not simply one problem added to another. The two pathogens amplify each other, creating a cycle of immune deterioration that is worse than either infection alone.16PubMed Central. Unlocking the complexity of HIV and Mycobacterium tuberculosis coinfection Sub-Saharan Africa, where HIV prevalence is highest, has borne the brunt of this overlap. TB remains the leading cause of death in people living with HIV worldwide.
Drug-Resistant Tuberculosis
Antibiotic resistance in TB is arguably the most alarming challenge in the fight against the disease. Strains resistant to both isoniazid and rifampicin, the two most powerful first-line drugs, are classified as multidrug-resistant TB, or MDR-TB. As of 2012 estimates, there were roughly 450,000 new MDR-TB cases and 170,000 deaths from it each year.17PubMed Central. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis Those numbers have continued to climb. A step beyond MDR-TB is extensively drug-resistant TB, or XDR-TB, which resists additional classes of backup drugs and is extraordinarily difficult to treat.
Drug resistance does not arise out of nowhere. It is driven primarily by weak health systems, incorrect or incomplete treatment courses, and transmission of resistant strains in communities, prisons, and healthcare facilities.17PubMed Central. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis Treating MDR-TB requires longer courses of second-line drugs, many of which have harsher side effects and are far more expensive. Treatment can take two years or longer, compared to the standard six to nine months. Newer diagnostic tools, such as the GeneXpert system, can identify both TB and rifampicin resistance from a sputum sample in about two hours, which helps clinicians start appropriate treatment much faster.18PubMed Central. The Value of GeneXpert MTB/RIF for Detection in Tuberculosis: A Bibliometrics-Based Analysis and Review
A Disease of Poverty
TB does not distribute itself randomly across populations. It clusters among the poor, the malnourished, and the marginalized. This pattern is not coincidental. Crowded housing, poor ventilation, limited access to healthcare, malnutrition, and high rates of other conditions like HIV and diabetes all converge in the same communities, creating the perfect environment for TB to thrive. Progress against the disease requires not just better drugs and diagnostics but also action on these social conditions: housing, social protection, and urban planning all play a role.19PubMed Central. The social determinants of tuberculosis: from evidence to action
A large case-control study in Peru quantified how steeply the gradient runs. Household poverty was strongly associated with TB, with the poorest tenth of households facing roughly twelve times the odds compared to the least poor tenth. The researchers estimated that TB burden could be halved simply by reducing poverty in the poorer half of households to the level of the less poor half.20PubMed Central. The social determinants of tuberculosis: a case-control study characterising pathways to equitable intervention in Peru Key personal risk factors also lined up along a poverty gradient: excess alcohol use, being underweight, smoking, HIV, diabetes, and a history of incarceration were all more common in poorer households. TB is concentrated in low- and middle-income countries and in specific populations within those countries, reflecting persistent social and economic inequality.21PubMed. The Global Epidemiology of Tuberculosis: Burden, Trends, and Determinants
Why Some People Are More Susceptible
Beyond poverty and immune suppression, your genetic makeup plays a role in whether TB bacteria that enter your lungs will be contained or will cause active disease. A multi-ancestry analysis estimated that about a quarter of the variability in TB susceptibility is heritable, shared across different ancestral populations. The study identified one region of the genome reaching strong statistical significance: a stretch within the HLA-II region, which encodes proteins central to how the immune system recognizes foreign invaders.22eLife. Multi-ancestry meta-analysis of host genetic susceptibility to tuberculosis identifies shared genetic architecture Rare genetic variants causing severe immune deficiencies can make some individuals highly vulnerable to TB from childhood, though these account for only a small fraction of cases.23PubMed Central. Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives
Genetics does not override the social and environmental factors, though. Even someone with a genetically resilient immune system can develop TB if they are malnourished, HIV-positive, or living in a crowded, poorly ventilated environment. The genetic contribution helps explain why, in a household where everyone is exposed, only one or two people may get sick. But population-level TB rates are driven far more by living conditions than by DNA.
Tuberculosis From Animals
Most human TB comes from person-to-person airborne transmission, but a distinct strain called Mycobacterium bovis causes what is known as zoonotic tuberculosis. Humans pick up M. bovis primarily by drinking unpasteurized milk from infected cattle or through close occupational contact with infected animals.24PubMed Central. Occupational exposure and challenges in tackling M. bovis at human-animal interface: a narrative review Zoonotic TB was once a major public health problem in industrialized countries. In the UK, it was widespread before milk pasteurization became standard practice in the mid-twentieth century.25PubMed. Human Mycobacterium bovis infection in the United Kingdom: Incidence, risks, control measures and review of the zoonotic aspects of bovine tuberculosis
In high-income countries today, zoonotic TB is rare thanks to pasteurization and cattle testing programs. But in parts of Africa, South Asia, and Latin America where pasteurization is less routine and people live in close proximity to livestock, M. bovis remains a genuine threat. The clinical disease it causes in humans looks very similar to standard TB and can be just as severe, though M. bovis is naturally resistant to pyrazinamide, one of the standard four drugs, which complicates treatment. Anyone who regularly consumes raw dairy products from regions where bovine TB is present should be aware of this risk.
What Happened to the BCG Vaccine
Most people outside North America have received the BCG vaccine, named for Bacille Calmette-Guérin, the weakened strain of M. bovis from which it is made. BCG is one of the most widely administered vaccines in history. It does provide meaningful protection against severe forms of childhood TB, particularly the kind that spreads to the brain and kills infants. But its effectiveness against pulmonary TB in adults is inconsistent, varying widely depending on the population, geographic region, and study. That inconsistency is a major reason why TB has not been controlled the way diseases like measles or polio have been. The vaccine also complicates diagnosis, because it can cause a positive tuberculin skin test in people who are not actually infected.26PubMed. Lack of correlation between BCG-induced tuberculin skin test sensitisation and protective immunity in cattle Newer blood-based tests that are not affected by prior BCG vaccination have helped work around this problem, and research into more effective TB vaccines is ongoing, though none has yet replaced BCG.
The search for a better vaccine has been one of the most frustrating chapters in modern infectious disease research. Several candidates have entered clinical trials over the past two decades, and a handful have shown encouraging early results. But TB’s ability to hide inside immune cells, go dormant for years, and evade the very immune responses that vaccines aim to strengthen makes it a uniquely difficult target. Until a substantially better vaccine arrives, controlling TB will continue to depend on finding and treating cases, preventing transmission through better living conditions, and addressing the social factors that keep the epidemic alive.